SNN vs BSX

For growth investors, Boston Scientific Corporation (BSX) is the stronger pick with 19.

9% revenue growth year-over-year, versus 6. 3% for Smith & Nephew plc (SNN). Smith & Nephew plc (SNN) offers the better valuation at 20. 9x trailing P/E (13. 4x forward), making it the more compelling value choice. Analysts rate Boston Scientific Corporation (BSX) a "Buy" — based on 43 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Smith & Nephew plc (SNN) is the cheapest at 20.

9x versus Boston Scientific Corporation at 29. 2x. On forward P/E, Smith & Nephew plc is actually cheaper at 13. 4x.

Over the past 5 years, Boston Scientific Corporation (BSX) delivered a total return of +31.

2%, compared to -23. 1% for Smith & Nephew plc (SNN). Over 10 years, the gap is even starker: BSX returned +155. 5% versus SNN's +9. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Boston Scientific Corporation (BSX) is the lower-risk stock at 0.

34β versus Smith & Nephew plc's 0. 59β — meaning SNN is approximately 73% more volatile than BSX relative to the S&P 500. On balance sheet safety, Boston Scientific Corporation (BSX) carries a lower debt/equity ratio of 51% versus 63% for Smith & Nephew plc — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Boston Scientific Corporation (BSX) is pulling ahead at 19.

9% versus 6. 3% for Smith & Nephew plc (SNN). On earnings-per-share growth, the picture is similar: Boston Scientific Corporation grew EPS 55. 2% year-over-year, compared to 53. 2% for Smith & Nephew plc. Over a 3-year CAGR, BSX leads at 16. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Boston Scientific Corporation (BSX) is the more profitable company, earning 14.

4% net margin versus 10. 1% for Smith & Nephew plc — meaning it keeps 14. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BSX leads at 19. 8% versus 16. 3% for SNN. At the gross margin level — before operating expenses — BSX leads at 69. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Smith & Nephew plc (SNN) trades at 13.

4x forward P/E versus 16. 7x for Boston Scientific Corporation — 3. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for BSX: 61. 4% to $91. 33.

In this comparison, SNN (2.

5% yield) pays a dividend. BSX does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Smith & Nephew plc (SNN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

59), 2. 5% yield). Both have compounded well over 10 years (SNN: +9. 8%, BSX: +155. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: SNN is a mid-cap quality compounder stock; BSX is a mid-cap high-growth stock. SNN pays a dividend while BSX does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.